 Home > Active Ingredient News > Antitumor Therapy > Front Oncol: Treatment outcome of patients with extensive-stage small cell lung cancer (ED-SCLC): retrospective analysis of 9994 patients from South Korea

Front Oncol: Treatment outcome of patients with extensive-stage small cell lung cancer (ED-SCLC): retrospective analysis of 9994 patients from South Korea

 Last Update: 2021-10-20
 Source: Internet
 Author: User

Tags

12 3 simplified

li ion cell

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Lung cancer is the leading cause of cancer-related deaths worldwide, and small cell lung cancer (SCLC) subtypes account for only 11%-14% of lung cancers
.

Biologically, SCLC is highly invasive and has the characteristics of high metastasis rate and early transmission

Lung cancer is the leading cause of cancer-related deaths worldwide, and small cell lung cancer (SCLC) subtypes account for only 11%-14% of lung cancers

A total of 9994 ED-SCLC patients were included in the study
.

The average age is 68 years old

A total of 9994 ED-SCLC patients were included in the study

During a median follow-up of 9.

Comparison of prognosis of first-line treatment

The median TFST time was 7.
1 months (95% CI, 6.
70-7.
23) in the CG group and 6.
1 months (95% CI, 5.
37-6.
77) in the SG group (P <0.
0001)
.

The median OS was 9.

The median TFST time was 7.

After the failure of the first-line chemotherapy, the second-line combination chemotherapy significantly improved the patient's OS compared with single-agent therapy, which were 6.

Comparison of prognosis of second-line treatment

Univariate analysis showed that age, male, hypertension, chronic obstructive pulmonary disease (COPD), without high cholesterol hyperlipidemia and diabetes , EP IP scheme and regimen and other factors were significantly associated with shorter compared to the OS
.

In the multivariate Cox proportional hazards regression analysis, all factors maintained independence for OS

Survival risk factors

In summary, the retrospective study of the large Korean population showed that the IP regimen can significantly improve the OS and TFST of patients with ED-SCLC in the first-line treatment
.

In summary, the retrospective study of the large Korean population showed that the IP regimen can significantly improve the OS and TFST of patients with ED-SCLC in the first-line treatment

Original source:

Lee JS, Kim S, Sung SY, Kim YH, Lee HW, Hong JH and Ko YH (2021) Treatment Outcomes of 9,994 Patients With Extensive-Disease Small-Cell Lung Cancer From a Retrospective Nationwide Population-Based Cohort in the Korean HIRA Database .
Front.
Oncol.
11:546672.
doi: 10.
3389/fonc.
2021.
546672

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.